UroSens Secures £2 Million Investment to commercialise Urine-Based Diagnostic Test for Bladder and Prostate Cancer

A cancer diagnostic company located in Sunderland and Cambridge which is developing a novel, non-invasive urine test for the detection of prostate and bladder cancer has secured a significant investment totalling £2m.
The company, UroSens Ltd, received the funding in a round led by Longwall Venture Partners, with participation from shareholders including Northstar Ventures, Esperante BV, Cambridge Capital Group and other existing shareholders.
The funding will enable UroSens to expand its commercial and technical team, finalise product development and commercialise its novel UroSens Mcm5-ELISA diagnostic test. Mcm5 is a protein which only appears when cells divide, and is an excellent marker for the presence of dividing cancer cells. The company is also seeking to undertake further clinical trials in Europe and the United States to expand the applications of the Mcm5 test. In addition, UroSens will continue the development of a Point of Care version of the Mcm5 test.

Continue reading

UroSens Receives £0.5 Million Funding and Enters into Clinical Trials for Bladder Cancer Diagnostic

Board of Directors Strengthened with Key Appointments.

Cambridge and Sunderland, UK, 17 June 2013: UroSens Ltd, a start-up diagnostic company developing novel, non-invasive urine tests for the detection of prostate and bladder cancer, has announced it has received £0.5M ($0.8M) investment and has entered into clinical trials to assess the accuracy of its novel UroSens Mcm5-ELISA diagnostic test for the detection of bladder cancer.
The funding has been received from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures’ Finance for Business North East Accelerator Fund, and existing investors. In addition to the £0.5M investment, UroSens has recently been awarded a grant of £250,000 from the Technology Strategy Board. The new funding will be used to enable UroSens to carry out a series of clinical studies, which will see the Company working with over 1,200 patients at four leading UK hospitals. The study is expected to be completed by October 2013. UroSens has secured ethics approval to conduct similar trials for the detection of prostate cancer.

Continue reading

Dr Sandy Primrose MBE appointed as non-Executive Chairman

Sandy Primrose

Urosens is pleased to announce the appointment of Dr Sandy Primrose MBE, (Arrayjet, Lab901, Amersham International), as non-Executive Chairman. His appointment enhances the commercial experience of Board members which will be of significant strategic importance in the management of the Company’s growth.

Dr Primrose commented, “I am delighted to accept the role as Chairman of UroSens at such an exciting time in the Company’s development. I look forward to working with the team as we move to commercialisation of our proprietary diagnostic test for bladder and prostate cancer.”

Technology Strategy Board GRD Development grant

UroSens Ltd, a uro-oncology diagnostic company, based on the Babraham Research Campus, Cambridge, UK, is pleased to announce that they have been awarded a £250,000 Technology Strategy Board GRD Development grant. This award will enable the company to finalise development of the proprietary Mcm5 ELISA immunoassay and undertake initial clinical trials for the detection of bladder and prostate cancer.
Dr Nick Miller-Jones, UroSens’ Chief Scientific Officer commented, “We are delighted with this award as it will enable our fully developed non-invasive urine-based diagnostic test to be evaluated in a clinical setting and take our platform another step closer to full commercialisation.”